406 related articles for article (PubMed ID: 19116303)
1. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
[TBL] [Abstract][Full Text] [Related]
2. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.
Burns JM; Flaherty PR; Nanavati P; Weidanz WP
Infect Immun; 2004 Oct; 72(10):5605-12. PubMed ID: 15385457
[TBL] [Abstract][Full Text] [Related]
3. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1.
Burns JM; Flaherty PR; Romero MM; Weidanz WP
Vaccine; 2003 May; 21(17-18):1843-52. PubMed ID: 12706668
[TBL] [Abstract][Full Text] [Related]
4. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.
Yoshida S; Nagumo H; Yokomine T; Araki H; Suzuki A; Matsuoka H
PLoS One; 2010 Oct; 5(10):e13727. PubMed ID: 21060850
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.
Xu H; Hodder AN; Yan H; Crewther PE; Anders RF; Good MF
J Immunol; 2000 Jul; 165(1):389-96. PubMed ID: 10861076
[TBL] [Abstract][Full Text] [Related]
6. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
[TBL] [Abstract][Full Text] [Related]
7. Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.
Biswas S; Spencer AJ; Forbes EK; Gilbert SC; Holder AA; Hill AV; Draper SJ
J Immunol; 2012 May; 188(10):5041-53. PubMed ID: 22504652
[TBL] [Abstract][Full Text] [Related]
8. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.
Rainczuk A; Scorza T; Spithill TW; Smooker PM
Infect Immun; 2004 Oct; 72(10):5565-73. PubMed ID: 15385453
[TBL] [Abstract][Full Text] [Related]
9. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.
Pichyangkul S; Tongtawe P; Kum-Arb U; Yongvanitchit K; Gettayacamin M; Hollingdale MR; Limsalakpetch A; Stewart VA; Lanar DE; Dutta S; Angov E; Ware LA; Bergmann-Leitner ES; House B; Voss G; Dubois MC; Cohen JD; Fukuda MM; Heppner DG; Miller RS
Vaccine; 2009 Dec; 28(2):452-62. PubMed ID: 19857448
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
12. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.
Rainczuk A; Smooker PM; Kedzierski L; Black CG; Coppel RL; Spithill TW
Vaccine; 2003 Jun; 21(21-22):3030-42. PubMed ID: 12798647
[TBL] [Abstract][Full Text] [Related]
13. Identification of antigenically active tryptic fragments of apical membrane antigen-1 (AMA1) of Plasmodium chabaudi malaria: strategies for assembly of immunologically active peptides.
Salvatore D; Hodder AN; Zeng W; Brown LE; Anders RF; Jackson DC
Vaccine; 2002 Oct; 20(29-30):3477-84. PubMed ID: 12297393
[TBL] [Abstract][Full Text] [Related]
14. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
Miura K; Zhou H; Diouf A; Moretz SE; Fay MP; Miller LH; Martin LB; Pierce MA; Ellis RD; Mullen GE; Long CA
Clin Vaccine Immunol; 2009 Jul; 16(7):963-8. PubMed ID: 19439523
[TBL] [Abstract][Full Text] [Related]
15. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
[TBL] [Abstract][Full Text] [Related]
16. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.
Johnson AH; Leke RG; Mendell NR; Shon D; Suh YJ; Bomba-Nkolo D; Tchinda V; Kouontchou S; Thuita LW; van der Wel AM; Thomas A; Stowers A; Saul A; Zhou A; Taylor DW; Quakyi IA
Infect Immun; 2004 May; 72(5):2762-71. PubMed ID: 15102786
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02
Berry AA; Gottlieb ER; Kouriba B; Diarra I; Thera MA; Dutta S; Coulibaly D; Ouattara A; Niangaly A; Kone AK; Traore K; Tolo Y; Mishcherkin V; Soisson L; Diggs CL; Blackwelder WC; Laurens MB; Sztein MB; Doumbo OK; Plowe CV; Lyke KE
Malar J; 2019 Jan; 18(1):13. PubMed ID: 30658710
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.
Stowers AW; Kennedy MC; Keegan BP; Saul A; Long CA; Miller LH
Infect Immun; 2002 Dec; 70(12):6961-7. PubMed ID: 12438375
[TBL] [Abstract][Full Text] [Related]
19. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
[TBL] [Abstract][Full Text] [Related]
20. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
Alaro JR; Lynch MM; Burns JM
Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
